UNIQURE NV (QURE)
NL0010696654 - Common Stock
UNIQURE NV
NASDAQ:QURE (1/3/2025, 8:00:01 PM)
After market: 17.674 -0.27 (-1.48%)17.94
-0.11 (-0.61%)
Company Profile
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 480 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Company Info
UNIQURE NV
Paasheuvelweg 25a
Amsterdam NOORD-HOLLAND 1105 BP
P: 31202406000
CEO: Matthew Kapusta
Employees: 480
Website: http://www.uniqure.com/
QURE News
21 days ago - The Motley FoolUp 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?a month ago - Investor's Business DailyUniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's DrugThe company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval.
a month ago - uniQure Inc.uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Diseasea month ago - uniQure Inc.uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the...
2 months ago - uniQure Inc.uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy2 months ago - uniQure Inc.uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe EpilepsyLEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative...
QURE Twits
Here you can normally see the latest stock twits on QURE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
